← Leaderboards
Lon S Schneider
University Of Southern California
$40,841,066
Attributed
$87,814,775
Total exposure
14
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.1M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$87,814,775 · 14
By mechanism
R01$72,999,046 · 8
P50$7,240,493 · 2
P30$4,545,214 · 2
UF1$2,429,633 · 1
U01$600,389 · 1
Top collaborators
- Terry Goldberg7 shared
- Philip D. Harvey7 shared
- Michael G Agadjanyan6 shared
- Clive Ballard6 shared
- Roberta Diaz Brinton6 shared
- Richard E Kennedy5 shared
- Kathleen E. Rodgers5 shared
- David Sultzer5 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Clive Ballard$1,923,359
- Don J Diamond$24,317,616
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseClinical TrialsParticipantCognitiveFutureCohortBiological MarkersImpaired CognitionClinical ResearchDementiaRandomizedBasePlacebosDiagnosisBrainSamplingDesignSafetyDoseAdverse EventEvaluationNeuropathologyTranslational Research
Grant awards (56)
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$6,580,973
R01 · FY2025 · AG
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.$5,308,961
R01 · FY2025 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,288,273
R01 · FY2025 · AG
Clinical Core$907,816
P30 · FY2025 · AG · contact PI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,243,861
R01 · FY2024 · AG
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,279,977
R01 · FY2023 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,408,617
R01 · FY2023 · AG
Clinical Core$868,383
P30 · FY2023 · AG · contact PI
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$714,437
R01 · FY2023 · AG · contact PI
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial$699,000
R01 · FY2023 · AG
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,552,351
R01 · FY2022 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.$2,680,709
R01 · FY2022 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$2,109,311
R01 · FY2022 · AG
Clinical Core$781,142
P30 · FY2022 · AG · contact PI
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$684,780
R01 · FY2022 · AG · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,370,815
R01 · FY2021 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$2,080,252
R01 · FY2021 · AG
Clinical Core$1,193,642
P30 · FY2021 · AG · contact PI
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$695,025
R01 · FY2021 · AG · contact PI
In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.$645,978
R01 · FY2021 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$1,505,130
R01 · FY2020 · AG
Clinical Core$794,231
P30 · FY2020 · AG · contact PI
(-)-Phenserine inhibition of neuronal death in Alzheimer's disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$702,380
R01 · FY2020 · AG · contact PI
In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.$645,978
R01 · FY2020 · AG
Novel Cognitive and Functional Measures for Alzheimer's Disease Prevention Trials: Sensitivity to Biomarkers$637,919
R01 · FY2020 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$400,184
R01 · FY2020 · AG
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$8,410,912
R01 · FY2019 · AG
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$1,505,129
R01 · FY2019 · AG
Clinical Core$732,587
P50 · FY2019 · AG · contact PI
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$725,263
R01 · FY2019 · AG · contact PI
In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.$645,978
R01 · FY2019 · AG
(-)-Phenserine inhibition of neuronal death in Alzheimerâs disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial$324,832
R01 · FY2019 · AG · contact PI
Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials$1,595,795
R01 · FY2018 · AG
Clinical Core$729,572
P50 · FY2018 · AG · contact PI
In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.$645,978
R01 · FY2018 · AG
Clinical Core$726,649
P50 · FY2017 · AG · contact PI
In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.$658,103
R01 · FY2017 · AG
Clinical Core$723,807
P50 · FY2016 · AG · contact PI
Clinical Core$720,501
P50 · FY2015 · AG · contact PI
CLINICAL CORE$713,905
P50 · FY2014 · AG · contact PI
Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I$2,429,633
UF1 · FY2013 · AG
CLINICAL CORE$690,043
P50 · FY2013 · AG · contact PI
Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and Improve$507,887
R01 · FY2013 · AG · contact PI
CLINICAL CORE$726,441
P50 · FY2012 · AG · contact PI
Longer-term Alzheimer Disease Studies to Improve Clinical Trials Methods Outcomes$547,116
R01 · FY2012 · AG · contact PI
Estrogen Receptor-beta phytoSERMs for Management of Menopause and Memory Decline$414,297
R01 · FY2012 · AG · contact PI
CLINICAL CORE$731,649
P50 · FY2011 · AG · contact PI
Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and Improve$561,235
R01 · FY2011 · AG · contact PI
Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated$534,946
R01 · FY2011 · AG · contact PI
CLINICAL CORE$745,339
P50 · FY2010 · AG · contact PI
Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated$686,664
R01 · FY2010 · AG · contact PI
Depression in Alzheimer's Disease Study 2 (DIADS-2)$115,916
U01 · FY2007 · MH · contact PI
Depression in Alzheimer's Disease Study 2 (DIADS-2)$119,286
U01 · FY2006 · MH · contact PI
Depression in Alzheimer's Disease Study 2 (DIADS-2)$121,875
U01 · FY2005 · MH
Depression in Alzheimer's Disease Study 2 (DIADS-2)$121,781
U01 · FY2004 · MH
Depression in Alzheimer's Disease Study 2 (DIADS-2)$121,531
U01 · FY2003 · MH